A federal advisory panel narrowly voted Thursday to recommend that the Food and Drug Administration loosen restrictions on injectable peptide compounds popular in wellness circles, even as FDA staff scientists flagged a thin body of evidence supporting their safety and effectiveness.
The panel’s 8-6 vote, with one abstention, backed allowing compounding pharmacies to produce peptides including BPC-157, TB-500, and KPV — substances that have attracted a devoted following among longevity-focused influencers and biohackers. The recommendation is not binding, and the FDA retains authority to set its own policy.
Background: From Restricted List to Center Stage
The FDA placed BPC-157 and TB-500 on a high-risk compounding list in 2023, citing concerns about unproven safety profiles for injectable use. Earlier this year, Health and Human Services Secretary Robert F. Kennedy Jr. announced he was removing peptides from that restricted list — a move that aligned with the MAHA movement’s broader push to expand patient access to alternative and emerging therapies.
Supporters of the compounds, including podcaster Joe Rogan and longevity influencer Gary Brecka, have helped drive public interest in peptides. More than two dozen speakers urged the panel to make the substances more widely available during public comment sessions that stretched across more than 18 hours of scheduled discussions over two days.
Scientific Concerns on the Record
FDA staff scientists, in their review ahead of Thursday’s vote, found little reliable data on peptide safety and effectiveness for the uses being proposed. Of five studies examining BPC-157 that the agency reviewed, all were short in duration and involved small sample sizes. Reviewers said they could locate no human studies at all for TB-500.
Dr. Elizabeth Rebello of the University of Texas MD Anderson Center voted against the recommendation, saying, “I’m concerned we’re responding to a market-induced demand rather than a decision based in solid science.”
The panel’s composition itself drew attention before the meeting. More than half a dozen individuals with ties to the peptide industry were added to the panel ahead of the gathering, a detail that critics noted when questioning whether the deliberations would adequately weigh safety data.
The Yes Votes: Patient and Physician Authority
Those who backed the recommendation framed the question largely as one of individual medical freedom and professional discretion. David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, explained his yes vote by saying, “It’s time to put this decision back in the hands of the patient, the physician and the pharmacist.”
That framing resonates with a core argument of the MAHA agenda — that federal agencies have at times restricted access to substances before patients and their doctors have had a genuine opportunity to weigh the risks and benefits for themselves. Panel members backing the motion appeared less persuaded by the gap in clinical evidence than by the principle of expanding prescriber and patient latitude.
What Comes Next
The panel was scheduled to vote Friday on three additional peptides, extending the two-day review. Whatever recommendations emerge, the FDA is not obligated to follow them. Agency leadership will ultimately decide whether and how to update compounding rules for these substances, a process that could unfold over months.
Kennedy’s earlier decision to remove peptides from the high-risk list signals the administration’s general direction, but formal regulatory changes require a separate rulemaking or guidance process. Compounding pharmacies currently operate in a legal gray zone on these compounds while that process plays out.
Idaho and the Broader MAHA Context
The peptide debate fits squarely within the larger MAHA-aligned push to revisit federal restrictions on a range of health products and practices — from regenerative agriculture inputs to compounded medications. Idaho, which has a strong tradition of supporting medical freedom and health autonomy, has a patient population that tracks developments like these closely. Idaho-based compounding pharmacies and the practitioners who work with them will be watching the FDA’s final disposition of the panel’s recommendation with direct professional interest.
The outcome of the full two-day review, including Friday’s votes, will help clarify whether the current administration’s stated commitment to expanding health options translates into concrete regulatory change for peptide access.